| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Fibroblast growth factor 21 (FGF 21) has been suggested as an independent factor for the protection of cardiovascular systém cells. We performed an anylasis to evaluate a possible association of FGF 21 levels with endothelial/hemostatik markers in asymptomati dyslipidemic individuals. We hypothesized that a potential protective actioncould be reflected in plasma elevationof FGF 21 in patients with adverse dyslipidemi phenotype. The study was conducted with asymptomatic patients (n=214), wubsequently divided into two groups (control group /CG/, n=66, 38 males, 28 females; dyslipidemic group /DLP/, n=148, 70 males, 78 females), according to apolipoprotein B (Apo B) and triglyceride levels. The plasma FGF 21 levels were measured by ELISA, while biochemical and endothelial/hemostatik markers were analysed by routine kit methods. In DLP (i.e. individuals with TG ? 1,5 mmol/l and/or apo B ? 1,2 g/l), plasma fibrinogen and FGF 21 levels were significantly higher (p { 0,01 and p { 0,001) compared to CG. We observed no significant differences in parameters of insulin resistence between groups after adjustment for sex, age and body mass index. The multiple regression analysis revealed that FGF 21 was associated positively with von Willebrand factor (vWF, p = 0,0031), tissue plasmonogen aktivátor (tPA, p=0,0099), and glucose (p=0,0313) only DLP individuals. The significant positive association of FGF 21 with vWF and tPA in subjects with noc linical symptoms of atherosclerosis could be related to emerging endothelial damage in dyslipidemic patients, although clinically asymptomatic.
- Fibroblast growth factor 21 (FGF 21) has been suggested as an independent factor for the protection of cardiovascular systém cells. We performed an anylasis to evaluate a possible association of FGF 21 levels with endothelial/hemostatik markers in asymptomati dyslipidemic individuals. We hypothesized that a potential protective actioncould be reflected in plasma elevationof FGF 21 in patients with adverse dyslipidemi phenotype. The study was conducted with asymptomatic patients (n=214), wubsequently divided into two groups (control group /CG/, n=66, 38 males, 28 females; dyslipidemic group /DLP/, n=148, 70 males, 78 females), according to apolipoprotein B (Apo B) and triglyceride levels. The plasma FGF 21 levels were measured by ELISA, while biochemical and endothelial/hemostatik markers were analysed by routine kit methods. In DLP (i.e. individuals with TG ? 1,5 mmol/l and/or apo B ? 1,2 g/l), plasma fibrinogen and FGF 21 levels were significantly higher (p { 0,01 and p { 0,001) compared to CG. We observed no significant differences in parameters of insulin resistence between groups after adjustment for sex, age and body mass index. The multiple regression analysis revealed that FGF 21 was associated positively with von Willebrand factor (vWF, p = 0,0031), tissue plasmonogen aktivátor (tPA, p=0,0099), and glucose (p=0,0313) only DLP individuals. The significant positive association of FGF 21 with vWF and tPA in subjects with noc linical symptoms of atherosclerosis could be related to emerging endothelial damage in dyslipidemic patients, although clinically asymptomatic. (en)
|
| Title
| - Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects
- Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects (en)
|
| skos:prefLabel
| - Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects
- Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects (en)
|
| skos:notation
| - RIV/61989592:15110/14:33151970!RIV15-MSM-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/14:33151970
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - tissue plasminogen activator; von Willebrand factor; endothelial dysfunction; dyslipidemia; factor 21; fibroblast growth (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...iv/tvurceVysledku
| - Vaverková, Helena
- Karásek, David
- Novotný, Dalibor
- Orság, Jiří
- Kubíčková, Veronika
|
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)